Clinical trial: A randomized controlled study on prevention of variceal rebleeding comparing nadolol + ligation vs. hepatic venous pressure gradient-guided pharmacological therapy

Alimentary Pharmacology and Therapeutics

Volumn 29, Issue 4, 2009, Pages 397-408

  Villanueva, C ^a,b   Aracil, C ^a   Colomo, A ^a,b   Lopez Balaguer, J M ^a   Piqueras, M ^a   Gonzalez, B ^a   Torras, X ^a,b   Guarner, C ^a,b   Balanzo, J ^a,b  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ISOSORBIDE 5 NITRATE; NADOLOL; PRAZOSIN;

ADULT; ARTICLE; ASPIRATION PNEUMONIA; BEDTIME DOSAGE; BRADYCARDIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DYSPHAGIA; ENDOSCOPIC SURGERY; ESOPHAGUS ULCER HEMORRHAGE; ESOPHAGUS VARICES BLEEDING; FEMALE; HEADACHE; HEPATIC VENOUS PRESSURE GRADIENT MONITORING; HUMAN; IMPOTENCE; INTERMETHOD COMPARISON; LIVER CIRRHOSIS; LIVER VEIN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; THORAX PAIN; VEIN LIGATION; VENOUS PRESSURE; WEAKNESS;

ANTIHYPERTENSIVE AGENTS; DRUG THERAPY, COMBINATION; ESOPHAGEAL AND GASTRIC VARICES; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL HEMORRHAGE; HEMODYNAMICS; HUMANS; ISOSORBIDE DINITRATE; LIGATION; LIVER CIRRHOSIS; MALE; MIDDLE AGED; NADOLOL; RECURRENCE; VENOUS PRESSURE;

EID: 58149335514     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2008.03880.x     Document Type: Article

References (33)

1. Sharara AI, Rockey DC. Gastroesophageal variceal hemorrhage. N Engl J Med 2001 345 : 669 81.
2. Boyer TD. Changing clinical practice with measurements of portal pressure. Hepatology 2004 39 : 283 5.
3. D'Amico G, Garcia-Pagan JC, Luca A, Bosch J. Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrhosis: a systematic review. Gastroenterology 2006 131 : 1611 24.
4. Groszmann RJ, Bosch J, Grace ND, et al. Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage. Gastroenterology 1990 99 : 1401 7.
5. Feu F, García-Pagán JC, Bosch J, et al. Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis. Lancet 1995 346 : 1056 9.
6. Abraldes JG, Tarantino I, Turnes J, Garcia-Pagan JC, Rodés J, Bosch J. Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. Hepatology 2003 37 : 902 8.
7. Villanueva C, López-Balaguer JM, Aracil C, et al. Maintenance of hemodynamic response to treatment for portal hypertension and influence on complications of cirrhosis. J Hepatol 2004 40 : 757 65.
8. D'Amico G, Pagliaro L, Bosch J. Pharmacological treatment of portal hypertension: an evidence-based approach. Semin Liver Dis 1999 19 : 475 505.
9. Garcia-Tsao G, Grace ND, Groszmann RJ, et al. Short-term effects of propranolol on portal pressure. Hepatology 1986 6 : 101 6.
10. Vorobioff J, Picabea E, Villavicencio R, et al. Acute and chronic hemodynamic effects of propranolol in unselected cirrhotic patients. Hepatology 1987 7 : 648 53.
11. García-Pagán JC, Navasa M, Bosch J, Bru C, Pizcueta P, Rodés J. Enhancement of portal pressure reduction by the association of isosorbide-5-mononitrate to propranolol administration in patients with cirrhosis. Hepatology 1990 11 : 230 8.
12. Garcia-Pagán JC, Feu F, Bosch J, Rodés J. Propranolol compared with propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis. A randomized controlled study. Ann Intern Med 1991 114 : 869 73.
13. Merkel C, Sacerdoti D, Bolognesi M, et al. Hemodynamic evaluation of the addition of isosorbide-5-mononitrate to nadolol in cirrhotic patients with insufficient response to the β-blocker alone. Hepatology 1997 26 : 34 9.
14. Morillas R, Planas R, Cabré E, et al. Propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis: long-term hemodynamic and renal effects. Hepatology 1994 20 : 1502 8.
15. Merkel C, Gatta A, Donada C, et al. Long-term effects of nadolol or nadolol plus isosorbide-5-mononitrate on renal function and ascites formation in patients with cirrhosis. Hepatology 1995 22 : 808 13.
16. Villanueva C, Aracil C, Balanzó J. What to do with non-responders. In : Groszmann RJ, Bosch J, eds. Portal Hypertension in the 21st Century. Dordrecht : Kluwer Academic Publishers, 2004 : 337 48.
17. Albillos A, García-Pagán JC, Iborra J, et al. Propranolol plus prazosin compared with propranolol plus isosorbide-5-mononitrate in the treatment of portal hypertension. Gastroenterology 1998 115 : 116 23.
18. Albillos A, Lledó JL, Rossi I, et al. Continuous prazosin administration in cirrhotic patients: effects on portal hemodynamics and on liver and renal function. Gastroenterology 1995 109 : 1257 65.
19. Blendis L, Wong F. Blocking the bleeding way. Gastroenterology 1998 115 : 230 2.
20. De Franchis R. Evolving consensus in portal hypertension. Report of the Baveno III consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 2005 43 : 167 76.
21. Lo GH, Lai KH, Cheng JS, et al. Endoscopic variceal ligation plus nadolol and sucralfate compared with ligation alone for the prevention of variceal rebleeding: a prospective, randomized trial. Hepatology 2000 32 : 461 5.
22. De la Peña J, Brullet E, Sánchez-Hernández E, et al. Variceal ligation plus nadolol compared with ligation for prophylaxis of variceal rebleeding: a multicenter trial. Hepatology 2005 41 : 572 8.
23. McCormick PA, Patch D, Greenslade L, Chin J, McIntyre N, Burroughs AK. Clinical vs hemodynamic response to drugs in portal hypertension. J Hepatol 1998 28 : 1015 9.
24. Bosch J, García-Pagán JC. Prevention of variceal rebleeding. Lancet 2003 361 : 952 4.
25. Villanueva C, Balanzó J, Novella M, et al. Nadolol plus isosorbide mononitrate compared with sclerotherapy for the prevention of variceal rebleeding. N Engl J Med 1996 334 : 1624 9.
26. Gournay J, Masliah C, Martin T, Perrin D, Galmiche JP. Isosorbide mononitrate and propranolol compared with propranolol alone for the prevention of variceal rebleeding. Hepatology 2000 31 : 1239 45.
27. Patch D, Sabin CA, Goulis J, et al. A randomized controlled trial of medical therapy versus endoscopic ligation for the prevention of variceal rebleeding in patients with cirrhosis. Gatroenterology 2002 123 : 1013 9.
28. Villanueva C, Miñana J, Ortiz J, et al. Endoscopic ligation compared with combined treatment with nadolol plus isosorbide mononitrate to prevent recurrent variceal bleeding. N Engl J Med 2001 345 : 647 55.
29. Bureau C, Péron JM, Alric L, et al. 'A la carte' treatment of portal hypertension: adapting therapy to hemodynamic response for the prevention of bleeding. Hepatology 2002 36 : 1361 6.
30. Thalheimer U, Mela M, Patch D, Burroughs AK. Targeting portal pressure measurements: a critical reappraisal. Hepatology 2004 39 : 286 90.
31. Groszmann RJ. Beta-adrenergic blockers and nitrovasodilators for the treatment of portal hypertension: the good, the bad, the ugly. Gastroenterology 1997 113 : 1794 7.
32. Grupta TK, Toruner M, Chung MK, Groszmann RJ. Endothelial dysfunction and decreased production of nitric oxide in the intrahepatic microcirculation of cirrhotic rats. Hepatology 1998 28 : 926 31.
33. Wilkinson SP, Bernardi M, Smith IK, Jowet TP, Slater JDH, Williams R. Effect of β-adrenergic blockade on the renin-angiotensin system, sodium excretion, and renal hemodynamics in cirrhosis with ascites. Gastroenterology 1977 73 : 659 63.